Trade Mark Journal No.2026/046 13 November 2026

WO0000001945620 (5,42)

Office of origin: United States of America

Date of International Registration:3 September 2026
Date of designation in the UK: 3 September 2026
Image for mark 1945620 CASPIAN THERAPEUTICS

Registration of this designation shall give no right to the exclusive use of the word "THERAPEUTICS".

International priority date claimed: 16 March 2026 (United States of America) (99705023)
Class 5
Pharmaceuticals for human use, namely, pharmaceutical preparations for treatment of diabetes and cardiometabolic, cardiovascular, menin, and metabolic related diseases, disorders, and conditions.
Class 42
Providing medical and scientific research information in the field of treatment of diabetes and cardiometabolic, cardiovascular, menin, and metabolic related diseases, disorders, and conditions, and clinical trials and post-market trials related to treatment of diabetes and cardiometabolic, cardiovascular, menin, and metabolic related diseases, disorders, and conditions; consulting services in the field of research and development of treatments of diabetes and cardiometabolic, cardiovascular, menin, and metabolic related diseases, disorders, and conditions; diabetes and cardiometabolic, cardiovascular, menin, and metabolic related diseases, disorders, and conditions treatment research and development.

Kura Oncology, Inc.

Representative: Anna E. Raimer Jones Day, 250 Vesey Street, New York NY 10281, UNITED STATES OF AMERICA